Method of treating high plasma cholesterol levels

a plasma cholesterol and plasma technology, applied in the direction of biocide, drug composition, metabolic disorders, etc., can solve the problems of hypercholesterolemia, and achieve the effect of reducing plasma cholesterol levels and reducing side effects

Inactive Publication Date: 2006-08-24
HADVARY PAUL +2
View PDF17 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0009] The subject invention provides a method of reducing plasma cholesterol levels in a hypercholesterolemic patient. This method comprises administering to the patient a therapeutically effective amount of a lipase inhibitor and a therapeutically effective amount of a bile acid sequestrant. A favored lipase inhibitor is orlistat and preferred bile acid sequestrants i...

Problems solved by technology

Hypercholesterolemia is a ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of treating high plasma cholesterol levels
  • Method of treating high plasma cholesterol levels
  • Method of treating high plasma cholesterol levels

Examples

Experimental program
Comparison scheme
Effect test

example 1

Study

[0066] The effect of a combination of Orlistat / XENICAL® and a bile acid sequestrant cholestyramine / QUANTALAN® on plasma cholesterol was examined.

[0067] Three hyper-cholesterolemic volunteers, one female, 2 males, started on Orlistat / XENICAL® b.i.d. for 4 weeks to establish a stable plasma cholesterol level: They continued on a combination of Orlistat / XENICAL® b.i.d. and cholestyramine / QUANTALAN® 4 g b.i.d. for a further 4 weeks, which was followed by a 4 week washout period. The effect of this treatment schedule on plasma cholesterol is reported in table 1.

[0068] The plasma cholesterol of all three individuals is reasonably stable at the end of 6 weeks treatment with Xenical b.i.d. After addition of Quantalan b.i.d. to the Xenical b.i.d. treatment plasma cholesterol clearly is reduced further by nearly 20%. The decrease is undoubtedly related to the Quantalan treatment: Upon cessation of Quantalan ingestion plasma cholesterol levels return to the values on Xenical ...

example 2

Orlistat Pharmaceutical Compositions

[0071]

QuantityIngredientmg / Capsuleorlistat120.00microcrystalline cellulose (AVICEL PH-101)93.60sodium starch glycolate (PRIMOJEL)7.20sodium lauryl sulfate7.20polyvinylpyrrolidone (Povidone (K-30))12.00purified Water*—talc0.24Total240.24mg

*Removed during processing

Procedure: [0072] 1. Blend orlistat, microcrystalline cellulose, and sodium starch glycolate in a suitable mixer. [0073] 2. Granulate with a solution of polyvinylpyrrolidone and sodium lauryl sulfate in purified water. [0074] 3. Pass the granulation through an extruder and pass the extrudate through a spheronizer to form pellets. [0075] 4. Dry the pellets at 30° C. [0076] 5. Add talc and mix.

[0077] 6. Fill into hard gelatin capsules.

IngredientQuantity mg / Capsuleorlistat60microcrystalline cellulose46.8sodium starch glycolate3.6sodium lauryl sulfate3.6polyvinylpyrrolidone6.0purified water*—talc0.12Total120.12mg

*Removed during processing.

Procedure: [0078] 1. Blend orlistat, micro...

example 3

Bile Acid Sequestrant Pharmaceutical Compositions

[0091]

QuantityIngredientmg / Capsulecholestyramine   4 gsilicium Dioxide0.495 gaspartame 0.05 gβ-carotene0.001 gpurified water*—Total 4.5 g

*Removed during processing

Procedure: [0092] 1. Blend colestyramine, and silicium dioxide in a suitable mixer. [0093] 2. Granulate with a solution / colloidal suspension of aspartame and beta-carotene in purified water. [0094] 3. Pass the granulation through an sieve. [0095] 4. Dry the granules at 60° C. [0096] 5. Pass the dry granulation through an sieve [0097] 6. Fill into sachets.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Timeaaaaaaaaaa
Mass flow rateaaaaaaaaaa
Mass flow rateaaaaaaaaaa
Login to view more

Abstract

A method prevents or treats diseases associated with high plasma cholesterol levels. In addition, this method reduces plasma cholesterol levels. The method comprises administering a lipase inhibitor, e.g. orlistat, and a pharmaceutically acceptable bile acid sequestrant.

Description

[0001] This application is a continuation of Ser. No. 10 / 313,409, filed Dec. 6, 2002, currently pending, which is a divisional of U.S. patent application Ser. No. 09 / 912,956, filed Jul. 25, 2001, currently pending. The entire contents of the above-identified applications are hereby incorporated by reference.BACKGROUND OF THE INVENTION [0002] 1. Field [0003] The present invention relates to a new method for the prevention and treatment of diseases associated with high plasma cholesterol levels (hypercholesterolemia). [0004] 2. Description [0005] Bile acid sequestrants have been proposed for use in lowering circulating blood cholesterol levels. Biologically, cholesterol is eliminated from the body by conversion to bile acids and excretion as neutral steroids. Bile acids are synthesized from cholesterol in the liver and enter the bile as glycine and taurine conjugates. They are released in salt form in bile during digestion and act as detergents to solubilize and consequently aid in di...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/724A61K31/365A61K31/00A61K47/10A61K31/16A61K31/21A61K31/337A61K31/717A61K31/718A61K31/785A61K45/06A61P3/06
CPCA61K31/00A61K31/365A61K31/785Y10S514/824A61P3/06A61P43/00A61K31/718
Inventor HADVARY, PAULLENGSFELD, HANSSTEFFEN, HANS
Owner HADVARY PAUL
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap